Article ; Online: More failure with solanezumab - this time in preclinical Alzheimer's disease.
Expert opinion on biological therapy
2024 Volume 24, Issue 3, Page(s) 119–123
Abstract: Introduction: There is no cure for Alzheimer's disease, which is the sixth leading cause of death in the USA. Lecanemab is anti-Aβ monoclonal antibody approved for the treatment of early Alzheimer's disease but is only marginally effective. Other ... ...
Abstract | Introduction: There is no cure for Alzheimer's disease, which is the sixth leading cause of death in the USA. Lecanemab is anti-Aβ monoclonal antibody approved for the treatment of early Alzheimer's disease but is only marginally effective. Other antibodies are being developed including solanezumab. Areas covered: A phase 3 clinical trial of solanezumab in preclinical Alzheimer's disease. In the A4 study, solanezumab did not reduce the decline in cognition or function and had no effect on brain amyloid burden. Expert opinion: After the poor results in the EXPEDITION series of trials, the development of solanezumab should have been terminated. The rationale for undertaking the A4 trial was questionable, and the lack of benefit was probable. The controversial approval of two anti-Aβ monoclonal antibodies (aducanumab and lecanemab) for the treatment of Alzheimer's disease by the US Food and Drug Administration (FDA), despite a high incidence of amyloid-related imagining abnormalities (ARIA), may be fueling this continuation of clinical development of agents such as solanezumab. The lesson from the A4 trial is that more careful/realistic consideration needs to be given before embarking on further phase 3 trials with anti-Aβ monoclonal antibodies. |
---|---|
MeSH term(s) | Humans ; Alzheimer Disease/drug therapy ; Amyloid beta-Peptides ; Brain ; Immunotherapy ; Antibodies, Monoclonal, Humanized |
Chemical Substances | solanezumab (5D6PWO0333) ; Amyloid beta-Peptides ; Antibodies, Monoclonal, Humanized |
Language | English |
Publishing date | 2024-03-03 |
Publishing country | England |
Document type | Journal Article ; Review |
ZDB-ID | 2052501-1 |
ISSN | 1744-7682 ; 1471-2598 |
ISSN (online) | 1744-7682 |
ISSN | 1471-2598 |
DOI | 10.1080/14712598.2024.2325551 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 6094: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.